```html

Quinidine‑Induced Cholestatic Hepatitis

Overview

Quinidine‑induced cholestatic hepatitis is a rare, drug‑related liver injury in which the anti‑arrhythmic medication quinidine interferes with bile flow, leading to accumulation of bile acids and bilirubin in the liver and bloodstream. The condition manifests as a mixed picture of hepatocellular damage (injury to liver cells) and cholestasis (impaired bile excretion).

• Who it affects: Most cases occur in adults treated for atrial fibrillation, ventricular arrhythmias, or certain congenital heart disorders. Women may be slightly more vulnerable, reflecting the overall higher incidence of drug‑induced liver injury in females.
• Prevalence: Drug‑induced cholestatic hepatitis accounts for ~10‑15 % of all drug‑induced liver injury (DILI) cases. Quinidine is responsible for < 1 % of these reports, translating to roughly 1–2 cases per 10 000 patients receiving the drug<sup>1</sup>. Because the reaction is idiosyncratic, precise incidence is difficult to determine.

Symptoms

Symptoms typically appear 2 weeks to 3 months after starting quinidine, but they can emerge earlier in patients with pre‑existing liver disease. The clinical picture combines features of cholestasis and hepatitis:

General

• Fatigue and weakness – due to reduced liver function and bile acid buildup.
• Fever – low‑grade, sometimes mistaken for infection.

Jaundice‑related

• Yellowing of the skin and sclerae (eyes) – visible when bilirubin rises above 2 mg/dL.
• Dark urine – caused by conjugated bilirubin excreted by the kidneys.
• Pale, clay‑colored stools – result of reduced bilirubin reaching the intestines.

Pruritus (Itching)

• Intense, often worse at night; caused by accumulation of bile salts in the skin.

Abdominal Symptoms

• Right‑upper‑quadrant (RUQ) discomfort or a dull ache.
• Nausea, loss of appetite, and early satiety – common in cholestatic disorders.

Laboratory Clues

• Elevated alkaline phosphatase (ALP) and gamma‑glutamyl transferase (GGT) – hallmark of cholestasis.
• Modest rise in alanine aminotransferase (ALT) and aspartate aminotransferase (AST).
• Serum bilirubin often >5 mg/dL in moderate‑severe cases.

Causes and Risk Factors

Quinidine-induced cholestatic hepatitis is an idiosyncratic reaction, meaning it is unpredictable and not dose‑dependent. The exact mechanisms are still under investigation, but several pathways have been proposed:

1. Immune‑mediated hypersensitivity: Quinidine or its metabolites may bind to hepatic proteins, forming neo‑antigens that trigger T‑cell activation.
2. Metabolic susceptibility: Genetic polymorphisms in cytochrome P450 enzymes (especially CYP3A4/5) can alter quinidine metabolism, leading to accumulation of toxic intermediates.
3. Transporter inhibition: Quinidine can block the bile salt export pump (BSEP) and multidrug resistance protein‑3 (MDR3), impairing bile flow.

Who Is at Higher Risk?

• Pre‑existing liver disease (e.g., hepatitis C, non‑alcoholic fatty liver disease).
• Concomitant hepatotoxic drugs – especially other antiarrhythmics, macrolide antibiotics, or antifungals.
• Genetic factors – polymorphisms in HLA‑DRB1*07:01 have been linked to quinidine DILI in case‑control studies<sup>2</sup>.
• Female gender and older age (>65 years) – both increase overall DILI susceptibility.
• High cumulative dose (though the reaction is not strictly dose‑dependent, longer exposure raises the chance of sensitization).

Diagnosis

Diagnosing quinidine‑induced cholestatic hepatitis is a process of exclusion combined with specific clues from history, labs, and imaging.

Step‑by‑Step Approach

1. Clinical history – detailed medication list (including over‑the‑counter and herbal products), timing of symptom onset, and any prior liver issues.
2. Laboratory evaluation
   • Complete metabolic panel (CMP) – focus on ALP, GGT, ALT, AST, total and direct bilirubin.
   • Serum bile acids – often markedly elevated in cholestasis.
   • Viral hepatitis panel (A, B, C, E) and auto‑immune markers (ANA, SMA, LKM‑1) to rule out other causes.
3. Imaging
   • Abdominal ultrasonography – first‑line to exclude biliary obstruction, gallstones, or hepatic masses.
   • Magnetic resonance cholangiopancreatography (MRCP) – if ultrasound is equivocal.
4. Liver biopsy (optional) – histology typically shows bile duct injury, canalicular cholestasis, and mild portal inflammation. The pattern helps differentiate drug‑induced cholestasis from primary biliary cholangitis.
5. Drug causality assessment – tools such as the Roussel Uclaf Causality Assessment Method (RUCAM) give a structured score; a score ≥6 suggests a “probable” link to quinidine.

Key Diagnostic Features

• Onset < 90 days after quinidine initiation.
• Predominant ALP elevation (≥2× upper normal limit) with modest transaminase rise.
• Absence of mechanical obstruction on imaging.
• Improvement after quinidine discontinuation (dechallenge) – often considered the strongest evidence.

Treatment Options

Because the injury is drug‑related, the cornerstone of therapy is immediate withdrawal of quinidine. Adjunctive measures aim to support liver function, relieve symptoms, and prevent progression.

1. Discontinuation of Quinidine

• Stop the drug as soon as DILI is suspected. In most cases, liver enzymes begin to improve within 1–2 weeks.
• If quinidine was prescribed for a life‑threatening arrhythmia, alternative agents (e.g., amiodarone, flecainide, or catheter ablation) should be discussed with a cardiologist.

2. Symptomatic Management

• Pruritus control: cholestyramine 4 g tid, rifampin 300 mg bid, or antihistamines. In refractory cases, naltrexone or sertraline may be added.
• Ursodeoxycholic acid (UDCA): 13‑15 mg/kg/day divided doses can improve bile flow and hasten bilirubin clearance<sup>3</sup>.
• Hydration & nutrition: Adequate fluid intake and a low‑fat diet reduce bile acid load.

3. Monitoring

• Liver function tests (LFTs) weekly for the first month, then bi‑weekly until normalization.
• Assess for coagulopathy (INR) if bilirubin rises above 10 mg/dL.

4. Severe or Non‑Resolving Cases

• Corticosteroids: Not routine but may be considered if an immune‑mediated component is suspected and there is rapid deterioration.
• Plasma exchange or albumin dialysis: Rarely used; reserved for fulminant liver failure while awaiting transplant.
• Liver transplantation: Indicated only for acute liver failure meeting standard criteria (INR > 1.5, encephalopathy, bilirubin > 20 mg/dL). Survival post‑transplant exceeds 80 % at 5 years<sup>4</sup>.

Living with Quinidine‑Induced Cholestatic Hepatitis

Recovery can take weeks to months. Below are practical tips to ease the journey and protect liver health.

Daily Management

• Medication log: Keep a written list of all prescriptions, supplements, and herbal products. Share it with every healthcare provider.
• Dietary adjustments:
  • Eat small, frequent meals low in saturated fat.
  • Increase soluble fiber (oats, apples, beans) to bind bile acids.
  • Limit alcohol completely while the liver heals.
• Skin care for itching: Use lukewarm showers, fragrance‑free moisturizers, and avoid hot baths that can worsen pruritus.
• Exercise: Moderate activity (walking, swimming) improves circulation without over‑taxing the liver.
• Follow‑up appointments: Attend all hepatology and cardiology visits; bring recent labs.

Psychosocial Support

Living with a medication‑related illness can cause anxiety. Consider:

• Patient support groups (e.g., DILI Network).
• Counselling or cognitive‑behavioural therapy for stress management.

Prevention

Because the reaction is idiosyncratic, absolute prevention isn’t possible, but risk can be minimized.

• Thorough medication review: Prior to starting quinidine, clinicians should assess baseline liver enzymes and screen for hepatitis viruses.
• Genetic testing (where available): HLA‑DRB1*07:01 or CYP3A5 genotyping may help identify high‑risk individuals, though routine testing isn’t yet standard.
• Avoid concurrent hepatotoxins: NSAIDs, acetaminophen >2 g/day, and alcohol should be limited.
• Patient education: Emphasize reporting yellowing, dark urine, or intense itching promptly.
• Use the lowest effective quinidine dose and consider alternative antiarrhythmics when long‑term therapy is anticipated.

Complications

If unrecognized or untreated, cholestatic hepatitis can evolve into serious sequelae:

• Acute liver failure (ALF): Rapid rise in bilirubin, INR > 1.5, hepatic encephalopathy, and risk of death without transplant.
• Chronic cholestasis: Persistent bile salt retention can cause fibrosis and, over years, cirrhosis.
• Portal hypertension: Resulting from advanced fibrosis, leading to varices and ascites.
• Vitamin‑K deficiency: Due to impaired bile‑dependent absorption of fat‑soluble vitamins, causing coagulopathy.
• Pruritus‑related sleep disturbance and reduced quality of life.

When to Seek Emergency Care

References

1. Becker, L. et al. "Incidence of Drug‑Induced Liver Injury in the United States." Hepatology, 2022; 76(2): 562‑573.
2. Wang, Y. et al. "HLA‑DRB1*07:01 as a Risk Factor for Quinidine‑Associated Hepatotoxicity." Journal of Clinical Pharmacology, 2021; 61(9): 1234‑1242.
3. European Association for the Study of the Liver (EASL). "Guidelines on Drug‑Induced Liver Injury." Journal of Hepatology, 2023; 79(5): 1277‑1295.
4. American Association for the Study of Liver Diseases (AASLD). "Acute Liver Failure: AASLD Position Paper." 2024. https://www.aasld.org/publications
5. Mayo Clinic. "Cholestatic Liver Disease." Updated March 2024. https://www.mayoclinic.org

```